WHAT IS CLAIMED IS:

1. A compound of formula I,



(I)

wherein,

X is Cl, Br, F, CN or NO_2;

G is (a) C_{1-7}alkyl which partially unsaturated and is substituted by hydroxy, or

(b) C_{1-4}alkyl substituted by NR^1R^2 or 4-tetrahydropyran;

R^1 is C_{2-7}alkyl substituted by hydroxy, C_{1-4}alkoxy, aryl, or heteroaryl;

R^2 is hydrogen or C_{1-7}alkyl;

or R^1 and R^2 together with the nitrogen to which they are attached form morpholine which may be optionally substituted by aryl or C_{1-7}alkyl;

W is a heterocycle of formula W1, W3, or W4;



W1 W3 W4

A is CR^4 or nitrogen;

B is CR^5 or nitrogen;

C is CR^6 or nitrogen;

E and F are such that (a) one is oxygen and the other is C(=O); or

(b) E is C(=O) and F is NR^7;

J and K are such that (a) J is nitrogen and K is CR^8; or

(b) J is CR^6 and K is nitrogen;

with the provisos that when W is of formula W3 and J is nitrogen, then at least one of A and B is nitrogen;

R^4 is H, halogen, or C_{1-4}alkyl optionally substituted by one to three halogens;

R^5 is (a) H,

(b) halo,

(c) OR^{12},

(d) SR^{12},

(e) C_{1-7}alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR^{12}, SR^{12}, $NR^{10}R^{11}$, or halo,

(f) C_{3-8}cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR^{12}, SR^{12}, or $NR^{10}R^{11}$,

(g) $(C=O)R^9$,

(h) $S(O)_mR^9$,

(i) $(C=O)OR^2$,

(j) $NHSO_2R^9$,

(k) nitro, or

(l) cyano;

R^6 is (a) H,

(b) halo,

(c) aryl,

(d) het,

(e) OR^{12},

(f) SR^{12},

(g) C_{1-7}alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR^{12}, SR^{12}, $NR^{10}R^{11}$, aryl, halo, C_{3-8}cycloalkyl optionally substituted by OR^{12}, or het attached through a carbon atom,

(h) $NR^{10}R^{11}$,

(i) C_{3-8}cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR^{12}, SR^{12}, or $NR^{10}R^{11}$,

(j) $(C=O)R^9$,

(k) $S(O)_mR^9$,

(l) $(C=O)OR^2$,

(m) $NHSO_2R^9$,

(n) nitro, or

(o) cyano;

R^7 is (a) H,

(b) C_{1-7}alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR^{12}, SR^{12}, $NR^{10}R^{11}$, or halo,

(c) C_{3-8}cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR^{12}, SR^{12}, or $NR^{10}R^{11}$,

(d) aryl, or

(e) het;

R^8 is (a) H,

(b) C_{1-7}alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR^{12}, SR^{12}, $NR^{10}R^{11}$, or halo,

(c) OR^{12}, or

(d) SR^{12};

R^9 is (a) C_{1-7}alkyl,

(b) $NR^{10}R^{11}$,

(c) aryl, or

(d) het, wherein said het is bound through a carbon atom;

R^{10} and R^{11} are independently

(a) H,

(b) aryl,

(c) C_{1-7}alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from $CONR^2R^2$, CO_2R^2, het, aryl, cyano, or halo,

(d) C_{2-7}alkyl which may be partially unsaturated and is substituted by one or more substituents selected from NR^2R^2, OR^2, or SR^2,

(e) C_{3-8}cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR^2, SR^2, or NR^2R^2, or

(f) R^{10} and R^{11} together with the nitrogen to which they are attached form a het;

R^{12} is (a) H,

(b) aryl,

(c) het

(d) C_{1-7}alkyl optionally substituted by aryl, het, or halogen,

(e) C_{2-7}alkyl substituted by OR^2, SR^2, or NR^2R^2, or

(f) C_{3-8}cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR^2, SR^2, or NR^2R^2;

each m is independently 1 or 2;

aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic, and aryl maybe optionally substituted with one or more substituents selected from halo, OH, cyano, NR^2R^2, CO_2R^2, CF_3, C_{1-6}alkoxy, and C_{1-6} alkyl which maybe further substituted by one to three SR^2, NR^2R^2, OR^2, or CO_2R^2 groups;

het is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from oxygen, sulfur, or nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group, and het may be optionally substituted with one or more substituents selected from halo, OH, cyano, phenyl, CO_2R^2, CF_3, C_{1-6}alkoxy, oxo, oxime, and C_{1-6} alkyl which may be further substituted by one to three SR^2, NR^2R^2, OR^2, or CO_2R^2 groups;

halo or halogen is F, Cl, Br, I;

1 represents the point of attachment between W and G;

2 represents the point of attachment between W and the carbonyl group of Formula (I);

and a pharmaceutically acceptable salt thereof;

2. A compound of claim 1 wherein W is of the formula W1.

3. A compound of claim 2 wherein W is of the formula W1.1.

4. A compound of claim 2 wherein W is of the formula W1.2.

5. A compound of claim 2 wherein W is of the formula W1.3.

6. A compound of claim 2 wherein W is of the formula W1.4.

7. A compound of claim 2 wherein W is of the formula W1.5.

8. A compound of claim 2 wherein W is of the formula W1.6.

9. A compound of claim 2 wherein W is of the formula W1.7.

10. A compound of claim 2 wherein W is of the formula W1.8.

11. A compound of claim 2 wherein W is of the formula W1.9.

12. A compound of claim 2 wherein W is of the formula W1.10.

13. A compound of claim 2 wherein W is of the formula W1.11.

14. A compound of claim 2 wherein W is of the formula W1.12.

15. A compound of claim 2 wherein W is of the formula W1.13.

16. A compound of claim 2 wherein W is of the formula W1.14.

17. A compound of claim 2 wherein W is of the formula W1.15.

18. A compound of claim 2 wherein W is of the formula W1.16.

19. A compound of claim 2 wherein W is of the formula W1.17.

20. A compound of claim 2 wherein W is of the formula W1.18.

21. A compound of claim 2 wherein W is of the formula W1.19.

22. A compound of claim 2 wherein W is of the formula W1.20.

23. A compound of claim 2 wherein W is of the formula W1.21.

24. A compound of claim 2 wherein W is of the formula W1.22.

25. A compound of claim 2 wherein W is of the formula W1.23.

26. A compound of claim 1 wherein W is of the formula W3.

27. A compound of claim 26 wherein W is of the formula W3.1.

28. A compound of claim 26 wherein W is of the formula W3.2.

29. A compound of claim 26 wherein W is of the formula W3.3.

30. A compound of claim 26 wherein W is of the formula W3.4.

31. A compound of claim 26 wherein W is of the formula W3.5.

32. A compound of claim 26 wherein W is of the formula W3.6.

33. A compound of claim 26 wherein W is of the formula W3.7.

34. A compound of claim 26 wherein W is of the formula W3.8.

35. A compound of claim 26 wherein W is of the formula W3.9.

36. A compound of claim 26 wherein W is of the formula W3.10.

37. A compound of claim 26 wherein W is of the formula W3.11.

38. A compound of claim 26 wherein W is of the formula W3.12.

39. A compound of claim 26 wherein W is of the formula W3.13.

40. A compound of claim 26 wherein W is of the formula W3.14.

41. A compound of claim 1 wherein W is of the formula W4.

42. The compound according to claim 1, wherein X is Cl.

43. The compound according to claim 1 wherein G is 4-morpholinylmethyl.

44. The compound according to claim 1 wherein G is 3-hydroxy-1-propynyl.

45. The compound according to claim 1 wherein G is tetrahydro-2*H*-pyran-4-ylmethyl.

46. The compound according to claim 1 which is

N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-2-oxo-2*H*-pyrano[2,3-*c*]pyridine-3-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)-1-oxo-1*H*-isochromene-3-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-1-oxo-6-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-isochromene-3-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-1-oxo-1*H*-isochromene-3-carboxamide;

N-(4-chlorobenzyl)-5-hydroxy-3-(3-hydroxy-1-propynyl)-8-oxo-7,8-dihydro[1,7]-naphthyridine-6-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)-1-oxo-1,2-dihydro-3-isoquinolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-1-oxo-1,2-dihydro-3-isoquinolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)[1,7]naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-8-ethoxy-4-hydroxy-6-(3-hydroxy-1-propynyl)[1,7]-naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)[1,7]naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-8-ethoxy-4-hydroxy-6-(4-morpholinylmethyl)[1,7]naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)[1,5]naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)[1,5]naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(tetrahydro-2*H*-pyran-4-ylmethyl)[1,5]-naphthyridine-3-carboxamide;

N-(4-chlorobenzyl)-8-hydroxy-2-(3-hydroxy-1-propynyl)pyrido[3,2-*d*]pyrimidine-7-carboxamide;

N-(4-chlorobenzyl)-8-hydroxy-2-(4-morpholinylmethyl)pyrido[3,2-*d*]pyrimidine-7-carboxamide;

N-(4-chlorobenzyl)-5-hydroxy-3-(4-morpholinylmethyl)[1,7]naphthyridine-6-carboxamide;

N-(4-chlorobenzyl)-5-hydroxy-3-(3-hydroxy-1-propynyl)[1,7]naphthyridine-6-carboxamide;

N-(4-chlorobenzyl)-5-hydroxy-3-(tetrahydro-2*H*-pyran-4-ylmethyl)[1,7]-naphthyridine-6-carboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(4-morpholinylmethyl)-3-isoquinolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(3-hydroxy-1-propynyl)-3-isoquinolinecarboxamide;

N-(4-chlorobenzyl)-4-hydroxy-6-(tetrahydro-2*H*-pyran-4-ylmethyl)-3-isoquinoline-carboxamide; or

a pharmaceutically acceptable salt thereof.

47. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

48. A method of treating or preventing a viral infection, comprising administering to a mammal in need of such treatment, a compound of formula (I),



(I)

wherein,

X is Cl, Br, F, CN or NO_2;

G is (a) C_{3-7}alkyl which is partially unsaturated and is substituted by hydroxy,

(b) C_{1-7}alkyl which is fully saturated and is substituted by hydroxy, or

(c) C_{1-4}alkyl substituted by NR^1R^2 or 4-tetrahydropyran;

R^1 is C_{2-7}alkyl substituted by hydroxy, C_{1-4}alkoxy, aryl, or heteroaryl;

R^2 is hydrogen or C_{1-7}alkyl;

or R^1 and R^2 together with the nitrogen to which they are attached form morpholine which may be optionally substituted by aryl or C_{1-7}alkyl;

W is a heterocycle of formula W1, W3, or W4;



W1



W3



W4

A is CR^4 or nitrogen;

B is CR^5 or nitrogen;

C is CR^6 or nitrogen;

E and F are such that (a) one is oxygen and the other is C(=O); or

(b) E is C(=O) and F is NR^7;

J and K are such that (a) J is nitrogen and K is CR^8; or

(b) J is CR^6 and K is nitrogen;

with the provisos that when W is of formula W3 and J is nitrogen, then at least one of A and B is nitrogen;

R^4 is H, halogen, or C_{1-4}alkyl optionally substituted by one to three halogens;

R^5 is (a) H,

(b) halo,

(c) OR^{12},

(d) SR^{12},

(e) C_{1-7}alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR^{12}, SR^{12}, $NR^{10}R^{11}$, or halo,

(f) C_{3-8}cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR^{12}, SR^{12}, or $NR^{10}R^{11}$,

(g) $(C=O)R^9$,

(h) $S(O)_mR^9$,

(i) $(C=O)OR^2$,

(j) $NHSO_2R^9$,

(k) nitro, or

(l) cyano;

R^6 is (a) H,

(b) halo,

(c) aryl,

(d) het,

(e) OR^{12},

(f) SR^{12},

(g) C_{1-7}alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR^{12}, SR^{12}, $NR^{10}R^{11}$, aryl, halo, C_{3-8}cycloalkyl optionally substituted by OR^{12}, or het attached through a carbon atom,

(h) $NR^{10}R^{11}$,

(i) C_{3-8}cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR^{12}, SR^{12}, or $NR^{10}R^{11}$,

(j) $(C=O)R^9$,

(k) $S(O)_mR^9$,

(l) $(C=O)OR^2$,

(m) $NHSO_2R^9$,

(n) nitro, or

(o) cyano;

R^7 is (a) H,

(b) C_{1-7}alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR^{12}, SR^{12}, $NR^{10}R^{11}$, or halo,

(c) C_{3-8}cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR^{12}, SR^{12}, or $NR^{10}R^{11}$,

(d) aryl, or

(e) het;

R^8 is (a) H,

(b) C_{1-7}alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR^{12}, SR^{12}, $NR^{10}R^{11}$, or halo,

(c) OR^{12}, or

(d) SR^{12};

R^9 is (a) C_{1-7}alkyl,

(b) $NR^{10}R^{11}$,

(c) aryl, or

(d) het, wherein said het is bound through a carbon atom;

R^{10} and R^{11} are independently

(a) H,

(b) aryl,

(c) C_{1-7}alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from $CONR^2R^2$, CO_2R^2, het, aryl, cyano, or halo,

(d) C_{2-7}alkyl which may be partially unsaturated and is substituted by one or more substituents selected from NR^2R^2, OR^2, or SR^2,

(e) C_{3-8}cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR^2, SR^2, or NR^2R^2, or

(f) R^{10} and R^{11} together with the nitrogen to which they are attached form a het;

R^{12} is (a) H,

(b) aryl,

(c) het

(d) C_{1-7}alkyl optionally substituted by aryl, het, or halogen,

(e) C_{2-7}alkyl substituted by OR^2, SR^2, or NR^2R^2, or

(f) C_{3-8}cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR^2, SR^2, or NR^2R^2;

each m is independently 1 or 2;

aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic, and aryl maybe optionally substituted with one or more substituents selected from halo, OH, cyano, NR^2R^2, CO_2R^2, CF_3, C_{1-6}alkoxy, and C_{1-6} alkyl which maybe further substituted by one to three SR^2, NR^2R^2, OR^2, or CO_2R^2 groups;

het is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from oxygen, sulfur, or nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group, and het may be optionally substituted with one or more substituents selected from halo, OH, cyano, phenyl, CO_2R^2, CF_3, C_{1-6}alkoxy, oxo, oxime, and C_{1-6} alkyl which may be further substituted by one to three SR^2, NR^2R^2, OR^2, or CO_2R^2 groups;

halo or halogen is F, Cl, Br, I;

1 represents the point of attachment between W and G;

2 represents the point of attachment between W and the carbonyl group of Formula (I);

and a pharmaceutically acceptable salt thereof;

49. The method according to claim 48 wherein said viral infection is a herpes virus infection.

50. The method according to claim 48 wherein said mammal is a human.

51. The method according to claim 48 wherein said mammal is a food animal or companion animal.

52. The method according to claim 48 wherein the infection is herpes simplex virus type 1 or 2, human herpes virus type, 6, 7, or 8, varicella zoster virus, human cytomegalovirus, or Epstein-Barr virus.

53. The method according to claim 48 wherein the infection is herpes simplex virus type 1 or 2, human herpes virus type 8, varicella zoster virus, human cytomegalovirus, or Epstein-Barr virus.

54. The method according to claim 48 wherein the amount administered is from about 0.1 to about 300 mg/kg of body weight.

55. The method according to claim 48 wherein the amount administered is from about 1 to about 30 mg/kg of body weight.

56. The method according to claim 48 wherein the compound is administered parenterally, topically, intravaginally, orally, or rectally.

57. A method for inhibiting a viral DNA polymerase, comprising contacting the polymerase with an effective inhibitory amount of a compound of the formula (I)



(I)

wherein,

X is Cl, Br, F, CN or NO_2;

G is (a) C_{3-7}alkyl which is partially unsaturated and is substituted by hydroxy,

(b) C_{1-7}alkyl which is fully saturated and is substituted by hydroxy, or

(c) C_{1-4}alkyl substituted by NR^1R^2 or 4-tetrahydropyran;

R^1 is C_{2-7}alkyl substituted by hydroxy, C_{1-4}alkoxy, aryl, or heteroaryl;

R^2 is hydrogen or C_{1-7}alkyl;

or R^1 and R^2 together with the nitrogen to which they are attached form morpholine which may be optionally substituted by aryl or C_{1-7}alkyl;

W is a heterocycle of formula W1, W3, or W4;



W1 W3 W4

A is CR^4 or nitrogen;

B is CR^5 or nitrogen;

C is CR^6 or nitrogen;

E and F are such that (a) one is oxygen and the other is C(=O); or

(b) E is C(=O) and F is NR^7;

J and K are such that (a) J is nitrogen and K is CR^8; or

(b) J is CR^6 and K is nitrogen;

with the provisos that when W is of formula W3 and J is nitrogen, then at least one of A and B is nitrogen;

R^4 is H, halogen, or C_{1-4}alkyl optionally substituted by one to three halogens;

R^5 is (a) H,

(b) halo,

(c) OR^{12},

(d) SR^{12},

(e) C_{1-7}alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR^{12}, SR^{12}, $NR^{10}R^{11}$, or halo,

(f) C_{3-8}cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR^{12}, SR^{12}, or $NR^{10}R^{11}$,

(g) $(C=O)R^9$,

(h) $S(O)_mR^9$,

(i) $(C=O)OR^2$,

(j) $NHSO_2R^9$,

(k) nitro, or

(l) cyano;

R^6 is (a) H,

(b) halo,

(c) aryl,

(d) het,

(e) OR^{12},

(f) SR^{12},

(g) C_{1-7}alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR^{12}, SR^{12}, $NR^{10}R^{11}$, aryl, halo, C_{3-8}cycloalkyl optionally substituted by OR^{12}, or het attached through a carbon atom,

(h) $NR^{10}R^{11}$,

(i) C_{3-8}cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR^{12}, SR^{12}, or $NR^{10}R^{11}$,

(j) $(C=O)R^9$,

(k) $S(O)_mR^9$,

(l) $(C=O)OR^2$,

(m) $NHSO_2R^9$,

(n) nitro, or

(o) cyano;

R^7 is (a) H,

(b) C_{1-7}alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR^{12}, SR^{12}, $NR^{10}R^{11}$, or halo,

(c) C_{3-8}cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR^{12}, SR^{12}, or $NR^{10}R^{11}$,

(d) aryl, or

(e) het;

R^8 is (a) H,

(b) C_{1-7}alkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from OR^{12}, SR^{12}, $NR^{10}R^{11}$, or halo,

(c) OR^{12}, or

(d) SR^{12};

R^9 is (a) C_{1-7}alkyl,

(b) $NR^{10}R^{11}$,

(c) aryl, or

(d) het, wherein said het is bound through a carbon atom;

R^{10} and R^{11} are independently

(a) H,

(b) aryl,

(c) C_{1-7}alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from $CONR^2R^2$, CO_2R^2, het, aryl, cyano, or halo,

(d) C_{2-7}alkyl which may be partially unsaturated and is substituted by one or more substituents selected from NR^2R^2, OR^2, or SR^2,

(e) C_{3-8}cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR^2, SR^2, or NR^2R^2, or

(f) R^{10} and R^{11} together with the nitrogen to which they are attached form a het;

R^{12} is (a) H,

(b) aryl,

(c) het

(d) C_{1-7}alkyl optionally substituted by aryl, het, or halogen,

(e) C_{2-7}alkyl substituted by OR^2, SR^2, or NR^2R^2, or

(f) C_{3-8}cycloalkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from halogen, OR^2, SR^2, or NR^2R^2;

each m is independently 1 or 2;

aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic, and aryl maybe optionally substituted with one or more substituents selected from halo, OH, cyano, NR^2R^2, CO_2R^2, CF_3, C_{1-6}alkoxy, and C_{1-6} alkyl which maybe further substituted by one to three SR^2, NR^2R^2, OR^2, or CO_2R^2 groups;

het is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from oxygen, sulfur, or nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group, and het may be optionally substituted with one or more substituents selected from halo, OH, cyano, phenyl, CO_2R^2, CF_3, C_{1-6}alkoxy, oxo, oxime, and C_{1-6} alkyl which may be further substituted by one to three SR^2, NR^2R^2, OR^2, or CO_2R^2 groups;

halo or halogen is F, Cl, Br, I;

1 represents the point of attachment between W and G;

2 represents the point of attachment between W and the carbonyl group of Formula (I);

and a pharmaceutically acceptable salt thereof;

58. The method of claim 57 wherein the polymerase and the compound are contacted *in vitro*.

59. The method of claim 57 wherein the polymerase and the compound are contacted *in vivo*.